Aryan Sonthalia

Yes. So a couple of questions. Firstly, the employee benefit expenses and the other expenses, those rose well ahead of revenue this quarter and pushed you into a loss. So on the levels you actually control, what's the plan to bring employee and other costs back in line with revenue and get back to flat and then growing? And on the HCRO front, it has been underperforming for the past couple of years.

A question on the dividend position. Since the AS 115 transition in 2019, the company hasn't been able to pay dividends due to the INR1,509 crores transition difference despite being profitable and cash rich. So any update on that front since we haven't heard on that matter in a while?